Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
New England Journal of Medicine2012Vol. 367(6), pp. 495–507
Citations Over TimeTop 1% of 2012 papers
Roy Fleischmann, Joel M. Kremer, John J. Cush, Hendrik Schulze‐Koops, Carol A. Connell, John Bradley, David Gruben, Gene V. Wallenstein, Samuel H. Zwillich, Keith S. Kanik
Abstract
In patients with active rheumatoid arthritis, tofacitinib monotherapy was associated with reductions in signs and symptoms of rheumatoid arthritis and improvement in physical function. (Funded by Pfizer; ORAL Solo ClinicalTrials.gov number, NCT00814307.).
Related Papers
- → FDA approves tofacitinib for rheumatoid arthritis(2012)97 cited
- → Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies(2016)31 cited
- → The off-label uses profile of tofacitinib in systemic rheumatic diseases(2020)13 cited
- → P088 REAL-WORLD EXPERIENCE WITH TOFACITINIB FOR THE MANAGEMENT OF CROHN’S COLITIS(2020)2 cited
- → AB0344 FACTORS WHICH CONTRIBUTE PERSISTENCY AND OPTIMAL USE OF TOFACITINIB; LESSONS FROM LONG TERM DAILY CLINICAL USE OF TOFACITINIB(2020)